Pierre Fabre Medicament
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO33%
Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Pierre Fabre Medicament on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| OCEANII NCT05195632 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 63 | 2024-05-27 (-6 mo) |
| COLUMBUS-AD NCT05270044 |
P3 | Active, not recruiting | Melanoma | 815 | 2027-03-31 |
| Tabelecleucel NCT04554914 |
P2 | Active, not recruiting | Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD) | 190 | 2027-06 |
| STX-241 FIH NCT06567015 |
P1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 171 | 2027-11-20 |
| STX-721/PFL-721 (Escalated) NCT06043817 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer; NSCLC | 345 | 2029-12-01 (+41 mo) |
| ALLELE NCT03394365 |
P3 | Recruiting | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications | 115 | 2030-05-31 (+115 mo) |
| VERT-002 NCT06669117 |
P1/2 | Recruiting | Solid Tumor; MET Alteration | 140 | 2030-10-21 |